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Test-treatment RCTs are susceptible to bias:
a review of the methodological quality of
randomized trials that evaluate diagnostic
tests
Lavinia Ferrante di Ruffano1, Jacqueline Dinnes1, Alice J. Sitch1, Chris Hyde2 and Jonathan J. Deeks1*
Abstract
Background: There is a growing recognition for the need to expand our evidence base for the clinical effectiveness
of diagnostic tests. Many international bodies are calling for diagnostic randomized controlled trials to provide the
most rigorous evidence of impact to patient health. Although these so-called test-treatment RCTs are very challenging
to undertake due to their methodological complexity, they have not been subjected to a systematic appraisal of their
methodological quality. The extent to which these trials may be producing biased results therefore remains unknown.
We set out to address this issue by conducting a methodological review of published test-treatment trials to determine
how often they implement adequate methods to limit bias and safeguard the validity of results.
Methods: We ascertained all test-treatment RCTs published 2004–2007, indexed in CENTRAL, including RCTs which
randomized patients to diagnostic tests and measured patient outcomes after treatment. Tests used for screening,
monitoring or prognosis were excluded. We assessed adequacy of sequence generation, allocation concealment and
intention-to-treat, appropriateness of primary analyses, blinding and reporting of power calculations, and extracted
study characteristics including the primary outcome.
Results: One hundred three trials compared 105 control with 119 experimental interventions, and reported 150
primary outcomes. Randomization and allocation concealment were adequate in 57 and 37% of trials. Blinding was
uncommon (patients 5%, clinicians 4%, outcome assessors 21%), as was an adequate intention-to-treat analysis (29%).
Overall 101 of 103 trials (98%) were at risk of bias, as judged using standard Cochrane criteria.
Conclusion: Test-treatment trials are particularly susceptible to attrition and inadequate primary analyses, lack of
blinding and under-powering. These weaknesses pose much greater methodological and practical challenges to
conducting reliable RCT evaluations of test-treatment strategies than standard treatment interventions. We suggest a
cautious approach that first examines whether a test-treatment intervention can accommodate the methodological
safeguards necessary to minimize bias, and highlight that test-treatment RCTs require different methods to ensure
reliability than standard treatment trials.
Please see the companion paper to this article: http://bmcmedresmethodol.biomedcentral.com/articles/10.1186/
s12874-016-0286-0.
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Background
Diagnostic tests are an essential component of the clini-
cian’s armory for deciding how best to manage their
patients. But how should clinicians identify the ‘best’ test
to use for a given indication? In an ideal world, such de-
cisions would be guided by large meta-analyses of rigor-
ous clinical effectiveness studies that summarize how
competing tests impact on downstream patient health.
In reality, there is a serious paucity of this evidence for
most diagnostic procedures in use today [1–7]. Ac-
knowledging that diagnostic accuracy studies alone
are insufficient to demonstrate the clinical utility of
tests, international bodies are increasingly calling for
randomized controlled trials to provide the most
rigorous evidence of impact to patient health [8, 9].
By analogy to the study design hierarchies for evaluat-
ing treatments, RCTs are commonly stated to be the
‘gold standard’ design for evaluating the effectiveness
of tests [7, 10–15].
These ‘test-treatment’ RCTs randomise patients to
undergo either a new test, or an existing test, measuring
the downstream health response after patients have re-
ceived subsequent treatment. Therefore when we seek to
evaluate tests we must compare entire management
pathways, called ‘test-treatment’ strategies, rather than
single interventions. The MRC-CUBE trial, for example,
evaluated whether testing dyspeptic patients for the bac-
terium Helicobacter pylori and treating those positive
with eradication therapy, would effectively reduce their
symptoms when compared to the standard approach of
giving acid suppression to all dyspeptic patients [16]
(Fig. 1). Test-treatment comparisons can take three gen-
eral formats, depending on the role the new test will
take within the existing strategy [17]. The MRC-CUBE
trial describes a replacement comparison where the new
test completely replaces the existing technique (in this
case no testing), however RCTs can also measure the
value of adding a new test either alongside the existing
strategy (e.g. the RATPAC trial [18]), or earlier in the
pathway, to select which patients will go on to receive
the existing tests (e.g. the RELAPSE trial [19]).
Test-treatment RCTs have however attracted criticism
[20]. Randomizing participants to testing strategies and
measuring patient outcomes after treatment, test-treatment
RCTs compare multi-staged interventions and face prac-
tical challenges in ensuring that they adequately control for
bias. As with other complex interventions, the ability to
blind could be compromised since test results must be
interpreted by clinicians, and diagnoses recounted to their
patients; it may therefore be impossible to eliminate
Fig. 1 Example of a replacement test-treatment RCT. Patients randomized to the experimental arm receive a test for the presence of Helicobacter
pylori, which is eradicated if found, while patients without bacterial infection are given proton pump inhibitors (acid suppression). Patients
randomized to the control arm receive no test and are all given proton pump inhibitors (acid suppression), reflecting standard care. The outcome
of the trial is eradication of dyspeptic symptoms at 12 months [16]
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performance and ascertainment bias [17, 21–23]. The need
for patients to progress through multiple interventions
(tests and treatments) could increase the proportion who
drop-out, and since the quality and information patients re-
ceive differ according to the interventions used, these trials
may also be susceptible to differential drop-out, placing
them at increased risk of attrition bias [22]. In addition,
sample sizes must be considerably larger in order to ac-
count for the probability that effects are only experienced
in patients who receive different care as a result of their
diagnoses; these trials may therefore risk being underpow-
ered to detect patient health effects [1, 22].
These features of trial design have been empirically
demonstrated to defend the RCT design against risks of
considerable bias [24–26], yet the ability of test-treatment
trials to implement methodological safeguards have not
been systematically examined. Recognizing the increasing
calls for RCTs to evaluate diagnostic tests, we undertook a
review of published test-treatment trials to appraise the
extent to which they are susceptible to the biases and
challenges that are claimed to confront them. We com-
pare our findings to similar reviews of pharmaceutical and
complex intervention trials to evaluate whether observed
inadequacies are due to the complex nature of test-treat
interventions.
Methods
The objective of this review was to describe the
frequency with which test-treatment trials implement
adequate methods to limit bias and safeguard the validity
of results.
Study sample
The Cochrane Central Register for Controlled Trials
(CENTRAL) includes RCTs identified from MEDLINE
and EMBASE, and records retrieved through hand-
searching undertaken by Cochrane Review Groups
and searching other sources. CENTRAL was searched
(25th May 2009) for reports of test-treatment RCTs
published between 2004 and 2007 (Table 1). Details
of the search and selection process have been reported
elsewhere [6, 27]. Briefly, eligible trials randomized pa-
tients between diagnostic testing strategies and measured
at least one patient outcome occurring after treatment.
Trials evaluating asymptomatic screening or monitoring
tests were excluded, as were non-English language reports.
Multiple reports of a single trial were assimilated through
cross-referencing.
Data extraction
Trials were classified by journal type, clinical specialty,
trial design, number of randomized groups, care setting
and type of diagnostic comparison (triage, add-on, re-
placement) as defined by Bossuyt and colleagues [28].
Methodological items assessed internal validity and trial
conduct according to: implementation of random se-
quence generation; allocation concealment; blinding of
participants, care-givers and outcome assessors; defin-
ition and description of primary outcomes; numbers of
cross-overs, drop-outs and other losses to follow-up;
analytical approach including use of intention-to-test;
and inclusion of sample size calculations. These items
were identified from three validated, internationally ac-
cepted standards for the conduct and reporting of RCTs:
the CONSORT checklist [29], the extension of the CON-
SORT statement for non-pharmacologic interventions
[30] and the Cochrane Collaboration’s ‘Risk of Bias’ tool
[31]. A standardized form was designed detailing the
criteria used as given in Table 2.
This tool was piloted on five randomly selected test-
treatment trials by three authors (JJD, CH, LFR) and modi-
fied to improve consistency. One reviewer undertook
extraction and quality assessment of all trials (LFR) and a
second reviewer (JaD) independently extracted and
assessed a 64% convenience sample (the first 66 eligible tri-
als). Disagreements were discussed to reach consensus
judgements. If uncertainties remained after discussion, the
data were checked by a third member of the team and
resolved by discussion. We assessed agreement using kappa
for a core subset of categorisations: agreement was substan-
tial for assessing the adequacy of sequence generation (k =
0.63 [95%CI 0.5–0.8]) and allocation concealment methods
(k = 0.71 [95%CI 0.5–0.8]), and most disagreements
concerned conflicting interpretations of whether meagre
descriptions should be judged as ‘unclear’ or ‘inadequate’.
Agreement was perfect when judging the presence of pa-
tient blinding (k = 1.00), near-perfect for outcome assessor
blinding (k = 0.90 [95%CI 0.8–1.0]) and substantial for
blinding care-providers (k = 0.65 [95%CI 0.3–1.0]); all dis-
crepancies were due to inaccuracies in data extraction and
the three disagreements regarding whether care-providers
had been masked owed to the misidentification of whether
personnel described as blind were treating physicians
performing the experimental or comparator test.
Table 1 Search strategy for test-treatment RCTs conducted in
CENTRAL Issue 2 2009
Search strategy Hits
#1 sensitiva or diagnose or diagnosis or diagnostica
in Clinical Trials
70,052
#2 randoma in Clinical Trials 335,175
#3 “study design” next “rct” in Clinical Trials 150,275
#4 (#2 OR #3) 449,453
#5 (#1 AND #4) 50,419
#6 (#5), from 2004 to 2007 12,892
adenotes truncation of search term
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We present a descriptive analysis using percentages
that reflect the categorical nature of the data. Although
we compare frequencies to enhance interpretation, test-
ing for statistical significance was inappropriate as we
did not evaluate specific hypotheses.
Results
Included trials
The search strategy retrieved 12,892 citations, yielding
103 eligible trials that compared 105 control interven-
tions with 119 experimental interventions. A broad
range of test-treatment strategies were evaluated across
a wide range of settings. A PRISMA flow diagram and
tabulated characteristics of included studies are available
elsewhere, along with an analysis of the quality of de-
scriptions of test-treatment interventions [27].
Outcomes
A total of 149 primary outcomes were reported by 97 of
the 103 trials (Table 3). Most studies had a single
primary outcome (79/103, 77%), 18 trials measured be-
tween 2 and 15 primary outcomes (median 3, IQR: 2–4),
and 6 trials failed to clearly specify a primary outcome.
Fifty-three trials reported 96 separate measurements of
health as a primary outcome, though in 22 of these trials
outcomes reflected short-term clinical response or dis-
ease status, and not downstream assessments directly
measuring the benefits of treatment (Table 3). In 38
trials the primary outcomes were process outcomes,
such as diagnostic and treatment decisions, timing, and
measures of appropriateness of care.
Half the trials (51%) detailed methods of measurement
for the primary outcome with adequate detail to repli-
cate, while neither the measurement method nor timing
were described by 17 trials (17%). Incomplete reports
most commonly omitted the time at which outcomes
were measured (missing for 43/57 partially reported out-
comes, 75%). Complete accounts of participant flow,
reporting numbers who were eligible, allocated, received
interventions, followed-up and analyzed (as recom-
mended by CONSORT [30]) were provided by 44 (43%)
trials, of which 20 (19%) also provided a full flow dia-
gram. One study (cluster-randomized) reported none of
Table 2 Definitions and criteria used to appraise the quality of
trial methods and conduct
1. Did methods of sequence generation adequately protect against
selection bias?
Clear description of method for allocating participants to study groups.
Quality judged as Adequate, Inadequate or Unclear using criteria
recommended by the Cochrane Collaboration [31].
2. Did methods of allocation concealment adequately protect
against selection bias?
Clear description of method for preventing knowledge or prediction of
group allocation amongst patients and care-providers. Quality judged as
Adequate, Inadequate or Unclear using criteria recommended by the
Cochrane Collaboration [31].
3. Were participants, care-providers and outcome assessors
blinded to test-treatment interventions?
Clear reports of whether participants, care-providers (those responsible for
patient management) and outcome assessors were masked to the identity of
tests used for decision-making, and a description of methods used to mask.
4. Were primary outcomes comprehensively reported?
Reports considered adequate with clear definition of the primary outcome
and description of method and timing of measurement. When the
primary outcome was not clearly defined, the outcome used in the
power calculation, or if not the outcome stated in the primary study
objective was considered as primary. The primary outcome was as ‘not
defined’ in the absence of this information [56]. Outcomes were classified
as patient based or process.
Method of measurement considered adequate if a validated tool used, if
non-validated but fully described tool used, or if rigorous criteria to assess
outcome were provided (e.g. the operational definition of a target condition
and test methods used to arrive at a diagnosis). Documentation considered
complete when the time at which the primary assessment should be
conducted was also made explicit.
5. For each group, is it clear whether some participants did not
receive the allocated intervention, were lost to follow-up, or were
not analyzed?
Clear and complete accounting of participant flow as detailed in
CONSORT [30], including use of a CONSORT diagram. Reporting considered
adequate if all five elements (Eligibility, Allocation, Receiving intervention,
Followed-up, Analyzed) were reported for all study groups, and if these
numbers agreed (e.g. if the number analyzed tallied with the numbers
randomized and lost to follow up).
Analysis according to allocated group–considered inadequate if
patients not analyzed according to allocated study group, regardless of
test(s) actually received.
Use of intention-to-treat (ITT)–clear statement that ITT principle was
used. Considered adequate if all study patients were analyzed as
randomized, and analyses were complete.
Exclusions and missing data–Clear description of numbers and reasons
for missing data due to: missing outcome responses, exclusion of
participants, and loss to follow-up; Description of methods used to deal
with missing data
Complete analysis–Analyses considered complete when no data were
missing due to exclusions, missing responses or loss to follow-up for the
primary outcome measured at the primary time-point. Magnitude of
attrition calculated per group for each trial by comparing numbers
randomized to numbers analyzed. Differential attrition considered as ≥5%
and ≥20% difference between arms, following the approach advocated by
the Centre for Evidence Based Medicine when judging the quality of
comparative evidence of effectiveness [57].
6. Was the primary analyses conducted appropriately?
Whole group analysis–Primary outcomes measured in subgroups of the
randomized population were considered Inadequate due to risk of
selection bias [58].
Table 2 Definitions and criteria used to appraise the quality of
trial methods and conduct (Continued)
Inconsistency–Use of different outcome assessment methods in each
group considered inadequate unless the outcome was a measure of test
performance (e.g. diagnostic yield or therapeutic yield).
7. How did studies determine sample size?
Reporting of a power calculation and outcome variable on which it was based,
extraction of target sample size and comparison to achieved sample size.
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these details, while the remaining 58 (56%) trials pub-
lished partial information.
Risk of bias from randomization, blinding and loss to-
follow-up
Methods of sequence generation and allocation conceal-
ment were adequate in 59 (57%) and 38 (37%) trials
(Table 4). Only 2 and 3 trials described inadequate
methods of sequence generation and allocation respect-
ively, the remaining majority provided insufficient
descriptions to judge.
Few trials reported blinding: 5 (5%) trials reported
blinding patients, 4 (4%) blinded care-providers and 22
(21%) blinded outcome assessors. Few trials explicitly
stated that blinding was not used. The trials that blinded
patients gave both experimental and control tests to all
patients (4/5) [32–35] or conducted all tests on samples
in a laboratory (1/5) [36] and masked patients from re-
sults. Treating clinicians were blinded by being provided
with standardized diagnostic reports in both arms [37],
by receiving sham diagnostic reports with actual diag-
nostic decision-making conducted by off-site non-
treating clinicians [35], or by non-disclosure of labora-
tory processes for the length of the trial [36].
Inadequate reporting of primary outcomes made ascer-
taining the identity of the outcome assessor difficult,
hence we often deduced this detail implicitly from the out-
come type and descriptions of measurement methods.
Blind outcome assessments were achieved using inde-
pendent expert panels in nine trials (9%), clinicians not
involved in patient care in six trials (6%), or by independ-
ent research assistants in 7 (7%).
Most trials (60, 58%) used objective primary outcomes
(e.g. all-cause mortality, healthcare cost) and standardized
measures of health response (e.g. maximal endurance to
exercise on the treadmill), and 27% (16/60) of these trials
performed blinded evaluations. Subjective primary out-
comes were less frequently blinded (7/39, 18%).
Fifty-nine (57%) studies were incomplete due to the
exclusion of participants after randomization (32, 31%)
and/or missing outcome data (52, 51%). Missing
outcome data were adequately explained in 26 of these
trials, 11 provided no description and 25 gave partial
accounts that were insufficient to determine the reasons
Table 3 Types of outcomes measured as primary endpoints in test-treatment RCTs
Outcome Type Trials, n (%) aOutcome measurements, n (%)
Patient
Symptom score 13 (25) 14 (9)
Adverse events 8 (15) 15 (10)
Function 8 (15) 11 (7)
Quality of life 5 (9) 17 (11)
Mortality 4 (8) 4 (3)
Health perception 2 (4) 5 (3)
Psychological morbidity 2 (4) 6 (4)
Absenteeism 1 (2) 1 (1)
Clinical status 9 (17) 9 (6)
Residual disease rate 7 (13) 7 (5)
Recurrent disease rate 6 (11) 7 (5)
Patient outcome total 53 (54) 96 (64)
Process
Therapeutic yield 17 (45) 20 (13)
Timing of care 8 (21) 8 (5)
Cost 7 (18) 7 (5)
Appropriateness of treatment decision 5 (13) 6 (4)
Diagnostic yield 4 (11) 5 (3)
Process outcome total 38 (39) 46 (31)
Composite outcome
Adverse patient and process event rate 7 (7) 7 (5)
Primary outcome not defined 6 (6) 0 (0)
Total 103 (100) 149 (100)
aMany trials included more than one primary outcome
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for missing data. The number of participants with miss-
ing data on the primary outcome in the 59 trials ranged
from 0.1 to 46% of randomized participants (median:
7.0%, IQR: 1.4%–17.6%) and 25 trials excluded more
than 10% of the original study population. The propor-
tion of missing data could not be calculated for four
trials due to poor reporting. Attrition differed by more
than 5% between arms in 21 comparisons made by 16
trials, and in 18 cases (86%) experimental interventions
lost the most participants. Attrition differed by more
than 20% in only one trial (Fig. 2). Procedures for hand-
ling missing data were poorly reported. The majority of
trials with missing data performed a complete case
analysis (61%, 36/59).
Nine trials (17%) imputed all missing values, while
three others imputed partial responses but excluded
wholly missing records. No trial reported using multiple
imputation methods.
Risk of bias due to inappropriate handling of primary
analyses
Although 72 (70%) of trials analyzed paitents according
to their allocated inteventions, the first requirement for
an intention-to-treat (ITT) analysis; only 30 (29%)
analyzed patients by their assigned groups and had no
missing data or imputed missing data, and so comply
with the most rigorous definition of intention-to-treat
analysis [29]. By comparison 31 trials (30%) failed to
analyze patients according to original allocations.
The majority of trials performed consistent between-
arm comparisons (82/103, 80%), either clearly using the
same measurement method across all study arms (63,
61%) or assessing test performance outcomes (e.g. diag-
nostic yield or therapeutic yield–% of patients allocated
a particular diagnosis or treatment) for which use of
different tests is appropriate (19, 18%). For three trials
the outcome was measured in different ways between
study arms. For example, a trial of patients with
suspected scaphoid fracture compared expedited MRI
imaging within 5-days of presentation with standard
testing (generally X-rays taking place 2 weeks after
immobilization) (Fig. 3). The primary outcome was un-
necessary initial immobilization, a treatment decision
measure based on observing normal MRI findings in the
experimental arm and normal findings on standard
imaging in the standard testing arm [38]. In order to
achieve true comparability, the same test would have to
be used across study arms to determine whether
immobilization was truly unnecessary. Consistency could
not be determined in the remaining 18 trials (17%) due
to lack of reporting.
Comparisons in nine trials (including six with consistent
outcome assessments) were judged as unfair due to ana-
lysis across improper subgroups; typically this entailed
Table 4 Methodological characteristics of test-treatment trials
Trial Quality Item Trials, n (%)
Randomized sequence allocation
Adequate 59 (57)
Inadequate 2 (2)
Unclear 42 (41)
Allocation concealment
Adequate 38 (37)
Inadequate 3 (3)
Unclear 62 (60)
Blinding
Patients 5 (5)
Care-providers 4 (4)
Outcome assessors 22 (21)
aSingle-blind 20 (19)
bDouble-blind 5 (5)
No blinding 78 (76)
Reporting of primary outcome assessment
Complete 53 (51)
Partial 33 (32)
Absent 17 (17)
Reporting of participant flow
Complete 44 (43)
Partial 58 (56)
Absent 1 (1)
Missing data
Complete 41 (40)
Attrition ≤10% 30 (29)
Attrition >10% 25 (24)
Incomplete, cannot calculate 4 (4)
Unclear if complete 3 (3)
Differential attrition
≥ 5% between arms 16 (16)
≥ 20% between arms 1 (1)
Intention-to-treat (ITT)
Patients analyzed as randomized 72 (70)
Complete or imputed data and analyzed
as randomized
30 (29)
Not conducted 31 (30)
Inconsistent outcome assessment 21 (20)
Inappropriate subgroup analysis 9 (9)
Sample size
Power calculation reported 81 (79)
cMedian trial sample size [IQR] 309 [153–731]
cMedian study arm sample size [IQR] 166 [72–297]
ablinding either patients or care-providers or outcome assessors; bblinding at
least two of: patients, care-providers or outcome assessors; cbased on
numbers randomized in all 103 trials
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measuring the primary outcome in a single diagnostic or
treatment subgroup, such as counting the frequency of
antibiotic prescription amongst patients diagnosed with
non-pneumonic respiratory tract infection (the study tar-
get condition) [39]. Since a patient’s eligibility for contrib-
uting to the primary outcome is defined by different tests
being evaluated in each arm, these studies are at risk of
having produced distorted measures of effect by compar-
ing two groups that are not analogous in patient charac-
teristics. When event rates were recalculated using the
more appropriate denominator of all randomized partici-
pants, the results of one trial changed direction (Fig. 2).
More than half (60, 58%) the studies were inadequate
in either their use of consistent outcome assessments,
analysis of patients by allocated group or avoidance of
inappropriate exclusions; only 19 trials (18%) performed
adequate primary analyses that minimized all assessed
risks of selection bias.
Reporting of power calculations in test-treatment RCTs
Power calculations were reported in 81 (79%) trials.
Nearly all related to a specific outcome parameter
(79/81, 98%) which matched the primary outcome in
72% (59/81). The remainder either did not define a
primary outcome (12, 15%), powered on a single
variable when the study evaluated multiple primary
outcomes (7, 9%), or used a different variable to
power the study (1, 1%).
Study populations ranged from 20 to 5341 participants
in individually-randomized trials, and 145 to 972 partici-
pants in cluster RCTs. Trials reporting power calcula-
tions had considerably larger study samples (median:
408, IQR:157–782) than those omitting this description
(median: 212, IQR: 108–304). Trials using patient pri-
mary outcomes had slightly larger median study samples
(median: 348, IQR: 163–772) compared to those using
process outcomes (median 247, IQR: 138–500).
Risk of type II error in test-treatment RCTs
Of the 79 trials in which a comparison between target
and achieved sample sizes could be made (two did not
provide power calculation results), 11 (14%) failed to
reach 75% of their estimated targets, including four that
recruited less than 50%. Of the 13 trials with a ≥5%
deficit, 5 (38%) reported difficulties in recruiting, 4
(31%) were stopped early due to either routine uptake of
the new test-treat strategy (n = 2), or significantly differ-
ent outcome rates to those expected. None provided
details of any stopping rules.
Discussion
We report on the methodological quality of test-treatment
trials unrestricted by clinical setting or publication. Of the
103 test-treatment RCTs we assessed, only two were not
found to be at risk of bias using the standard Cochrane
criteria. In many instances our appraisals were hindered
Fig. 2 Example of an inappropriate subgroup comparison, leading to differential attrition of >20%. This triage comparison trial compared a
strategy of only undertaking diagnostic laparoscopy in women who had failed first-line intrauterine insemination (IUI) rather than undertaking
laparoscopy in all women prior to fertility treatment [59]. The primary outcome was the proportion of women experiencing a change in fertility
treatment from IUI. The published analysis used the proportion of participants undergoing diagnostic laparoscopy as the denominator rather than
the number randomized in each arm. The authors analysis reported a non-significant small increase (experimental 13/23 (56%), control 31/64
(48%); OR = 1.4 [95%CI: 0.5–3.6]). However when the full study population is used a significant decrease in the proportion of women receiving a
change in treatment is observed (experimental 13/77 (17%), control 31/77 (40%); OR = 0.3 [95%CI: 0.14–0.64]). Excluding participants who did not
receive a laparoscopy (70% of experimental group participants, and 17% of comparator arm participants) all experimental group patients who
became pregnant during intrauterine insemination treatment were excluded from the effectiveness measurement introducing selection bias
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by insufficient reporting of trial conduct and methods.
The choice of primary outcomes raise some concern re-
garding the usefulness of test-treatment trials, since the
majority aimed to answer intermediate questions of
process or short-term health impact, whose relevance to
long-term health may be questionable [40]. Most trials
failed to protect against selection bias by implementing in-
adequate allocation concealment and/or randomization
measures, and this risk was amplified in the two-thirds of
trials that performed suboptimal analyses on incomplete
populations. The rarity of blinding suggests that approxi-
mately 95% of trials produced results that risk reflecting
the expectations of participants, clinicians and trial-
ists, particularly the 30% of studies that measured
subjective outcomes in unblinded fashion and so were
also at high risk of ascertainment bias. These features
are all known to cause overestimated treatment
effects and potentially spurious findings in trials of
treatment interventions [24–26, 41].
Comparison to existing reviews of trial quality
A previous review of test-treatment RCTs [15] was
limited to a sample of 50 published trials ascertained
from searches of the top six generalist medical journals
(without year restrictions), which reported more favor-
able frequencies of methodological safeguards than
found here (only 10% of our 103 trials were published
in these six journals). Blinding of any type was re-
ported in a similar proportion of trials (30% vs 24%),
but higher proportions reported allocation conceal-
ment (50% vs 37%) and maintained attrition at <10%
(80% vs 69%). Differences of this magnitude could
occur by chance, but may also reflect better reporting
and methodological quality in RCTs published in top
generalist medical journals.
Similar reviews have assessed the methodological qual-
ity of treatment intervention trials, and we compare our
findings for randomization, allocation concealment and
blinding with those of an assimilated analysis of 1973
Fig. 3 Example of inconsistent measurement of the primary outcome between study arms. The primary outcome of the number of days
unnecessarily immobilized is not comparable as the assessment that the plaster is unnecessary and can be removed is determined using MRI
findings in the experimental arm and by routine testing (commonly X-ray) in the comparator arm [38]
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trials of mainly pharmaceutical interventions [26]. In
test-treatment trials, methods of sequence generation
(57%) and allocation concealment (37%) were more
often adequate than in RCTs of treatments (25 and
23%). However, double-blinding was reported in 56%
(590/1057) of intervention trials compared with only 5%
of test-treatment RCTs (5/103) (based on at least two
categories of individual being blinded). Conduct of ITT
analyses were rarer amongst test-treatment trials (30%)
than treatment trials (48%–57% [42, 43]), and rates of at-
trition higher, with 25% of our sample excluding >10%
of participants compared to only 10% of treatment trials
[42, 44]. Lastly, although our review found power calcu-
lations were reported more frequently by test-treatment
trials (79% vs. 27–45% [30, 46]) median sample sizes
were somewhat smaller than the 425 per arm (IQR:
158–1041) recruited by 225 contemporary (2005–6)
parallel-group RCTs [45].
On the other hand, our findings are broadly consistent
with appraisals of complex intervention trials; ITT ana-
lyses were found in 24% (vs. 30%), although power calcu-
lations were reported considerably less often than by
test-treatment trials (28% vs 79%) [46]. Rates of blinding
are also similar to reviews of surgical trials that reported
blinding of patients in 8–15%, care-providers in 0–8%
and outcome assessment in 17–35% [47, 48]. Reviews
directly comparing non-pharmacologic and pharmaceut-
ical RCTs for osteoarthritis also showed that blinding is
significantly less common in complex intervention trials,
particularly for patients (24–26% vs. 96–97%) and care-
providers (6% vs. 82%) [48, 49].
Interpretation of findings and implications for practice
The low quality of test-treatment RCTs is partly explained
by the suboptimal quality observed across all types of
RCT [26], yet the above comparisons indicate that it also
reflects methodological challenges that specifically affect
test-treatment trials due to the multi-staged nature of
their interventions.
As with therapeutic complex intervention trials, the
scarcity of blinding in test-treatment RCTs almost cer-
tainly reflects the practical and ethical difficulties involved
in blinding all trial participants (patients, care-providers
and assessors) from multiple elements of lengthy care
pathways, which may be invasive and are typified by active
patient and clinician participation. For the majority of
test-treatment comparisons blinding is likely to be impos-
sible, particularly for clinicians who would need to be
masked from the test(s) being used, and possibly also from
the test result itself. It is difficult to imagine many clinical
situations in which this would be ethical or practicable.
Then again, the degree to which not blinding exposes
test-treatment trials to bias cannot necessarily be dir-
ectly inferred from what we know of treatment trials.
Diagnostic tests are decision-making tools, hence it is
possible that blinding itself can have unintended conse-
quences on the validity of trial results, for example from
removing the clinician’s role from decision-making. In
one of our cohort, patients with suspected pulmonary
embolism (PE) received treatment directed either by re-
sults of a standard ventilation-perfusion (V/Q) scan, or
by an initial triage test (‘BIOPED’ combined test: D-
dimer blood test, alveolar dead space measurement, and
Well’s seven-variable clinical model) followed by V/Q
scan if PE could not be ruled out [35]. Interpretation of
BIOPED results was passed to non-treating clinicians
(trial investigators not involved in patient care) to decide
which patients should go on to receive a V/Q scan:
BIOPED negative patients (i.e. PE ruled out) received a
sham V/Q procedure, while test positives received a true
V/Q scan. In order to maintain blinding of clinicians, a
fake negative nuclear medicine report was sent to the
physicians of patients who had received a sham V/Q
scan. By circumventing the contribution of the treating
clinician, this study runs the risk of producing treatment
effects which could never be reproduced in reality; that is
to say its applicability to similar diagnostic settings in prac-
tice has been compromised. In short, blinding clinicians is
unlikely to prevent performance bias in test-treatment
trials, and may even distort the effects we are trying to ob-
serve. Blinding of patients and outcome assessments is
likely to be particularly important when measuring sub-
jective outcomes that are sensitive to patient and clinician
expectations. Research is needed to determine the extent
to which this will be feasible, and is important.
We also provide empirical confirmation that test-
treatment trials are particularly susceptible to attrition
and lack of power. High rates of missing outcome data
could indicate that test-treatment RCTs are at an in-
creased risk of losing participants after randomization,
perhaps due to the practical difficulties of maintaining
patient compliance throughout numerous interventions,
longer study periods and potentially more intensive
follow-up regimes. The lack of blinding in these trials may
also drive drop-out rates and missing responses, since
patients dissatisfied or disillusioned with their diagnostic
allocations may have been less motivated to comply with
the trial’s follow-up protocol. This was documented by
authors of one trial evaluating the benefits of investigating
patients with suspected fractures using an MRI scan in
addition to the usual X-ray, who reported that patients
randomized to the MRI arm were more likely to return
their questionnaires than those who knew they had not
received the new technology [50].
The lower sample sizes observed were unexpected
since test-treatment sample sizes generally need to be
substantially larger than is usual for treatment trials as
health effects are diluted by the subgroup of patients
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who would receive the same diagnosis and treatment by
both test-treat strategies under evaluation [22, 23, 51].
Although we have not considered the validity of the
justification of sample sizes in each individual study, the
lower than average sample sizes indicate that test-
treatment RCTs are likely to be underpowered to detect
differences in downstream patient health.
Often an RCT may be used to assess whether there
are reductions in the proportions of patients undergoing
inappropriate additional investigations or interventions.
We observed instances where results were computed
based on the numbers undergoing additional investiga-
tions or interventions, rather than the total numbers
randomized. This introduces bias as those receiving
additional testing and treatment are determined post-
randomization and are not based on the same informa-
tion in both study arms [52].
Despite these practical challenges, there is no theoretical
reason why test-treatment RCTs cannot minimize the
risks of attrition bias and type II error to a similar degree
as standard treatment RCTs. Ensuring that published trials
are internally valid, however, will require current methods
of critical appraisal to be adapted to reflect the particular
requirements of test-treatment interventions.
Strengths and limitations
Our study examines the internal validity of a systematically-
derived and unrestricted group of test-treatment RCTs
measuring patient outcomes. The cohort comprises a di-
verse range of test-treatment interventions, conducted
across a wide range of clinical settings. We have previously
shown [6] that our search was close to complete.
Two factors may have impacted on the reliability of
our estimate of trial quality. We only undertook dupli-
cate data extraction for 64% of our sample, however the
perfect or near-perfect agreement we found indicates the
likelihood of error is small. Lastly, the quality of trial
reporting and conduct has improved over the last
15 years [53, 54] so it is possible that trials published
since 2007 are of better quality. However, since no
guidance on how to resolve the unique issues posed by
test-treatment trial designs has been disseminated in the
interim, improvements are unlikely to be far-reaching.
Conclusion and recommendations
There is a clear need to improve the conduct and
reporting of test-treatment RCTS, and guidance for trial-
ists to resolve these issues is urgently needed. Existing
RCT quality checklists, such as those provided by NICE
[55] and Cochrane [31], do not currently address the
methodological peculiarities of test-treatment interven-
tions, though could be amended to do so.
Our review emphasizes methodological weaknesses
intrinsic to the RCT design when used to evaluate test-
treatment interventions. Minimizing attrition poses a
much greater practical difficulty for test-treatment trial-
ists than those undertaking standard trials, while blind-
ing and adequate powering present additional challenges
which in many circumstances may be impossible to
overcome. These pose considerable obstacles to success-
fully completing test-treatment trials, particularly when
viewed alongside evidence that test-treatment interven-
tions are difficult to capture and translate into trial proto-
cols [27], and that they impact on patient health in
numerous and highly complicated ways [51]. While the
RCT notionally remains the ideal design to evaluate clin-
ical effectiveness, a likely implication of our findings is
that it may well have limited success when used to evalu-
ate certain test-treatment interventions.
When an RCT design is used, our findings highlight
that standard RCT methods need to be tailored to suit
test-treatment interventions. Since blinding clinicians is
unlikely to be feasible, the use of more detailed or rigid
protocols may serve to limit systematic differences in
care provision that occur beyond those generated by
using different diagnostic tests for decision-making.
Close accounting of clinical behavior, including test use,
decision-making and treatment use, will assist investiga-
tors to discern between effects due to genuine divergence
in test performance from those that reflect artefacts of
study design. The noncomparability of outcome measure-
ments between study arms is another unique challenge to
test-treatment RCTs that occurs because the intervention
we wish to evaluate is itself designed to categorize patients
into subgroups. From a clinical perspective it is intuitive
to want to know how patients fare between particular
treatment categories in order to gauge the appropriateness
of decision-making, however the introduction of a third
test to ensure comparability of outcomes in all partici-
pants may prove practically difficult. Finally, adequate
powering requires trialists to inflate estimates based on
standard treatment effects by the projected fraction of
participants who would receive a difference in diagnosis
between test-treatment interventions [51], leading to un-
attainable patient recruitment targets.
We maintain that protection against bias in RCT stud-
ies is not often feasible, and thus these designs should be
mandated with care. First, it is essential to examine
whether the test-treatment strategies being compared
can accommodate the key methodological safeguards, in
particular adequate powering, consistent outcome meas-
urement and outcome blinding. In cases where it is im-
possible to control for bias, smaller scale observational
studies and modelling may prove to be more valid. Ur-
gent research is needed to establish: whether blinding is
feasible, the impact that not blinding has on the reliabil-
ity of trial results, and–importantly–the validity of alter-
native linked-evidence approaches.
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